New CLL combo aims for Long-Term remission without lifelong pills

NCT ID NCT07624799

Not yet recruiting Disease control Sponsor: French Innovative Leukemia Organisation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests a new drug called pirtobrutinib combined with a short course of chemotherapy in 82 fit patients with untreated CLL. The goal is to achieve deep remission with undetectable cancer cells in the blood at 24 months. The treatment lasts only 15 months, aiming to control the disease long-term while reducing side effects and the risk of secondary cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pirtobrutinib (a targeted drug) plus a short course of chemotherapy (fludarabine, cyclophosphamide, obinutuzumab)
What this could lead to: If successful, this could offer a fixed-duration treatment that controls CLL deeply for years without needing lifelong medication.
What could go wrong: This is an early phase II trial with only 82 participants. Risks include side effects from chemotherapy and the drug, and the approach may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Leukemia, B-Cell

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLL (CHRONIC LYMPHOCYTIC LEUKEMIA)

More trials for these conditions

Other studies related to the condition(s) this trial covers.